Borden E C, Balkwill F R
Cancer. 1984 Feb 1;53(3 Suppl):783-9. doi: 10.1002/1097-0142(19840201)53:3+<783::aid-cncr2820531329>3.0.co;2-i.
Preclinical and clinical studies suggest interferons and interferon inducers have antitumor activity for breast carcinoma. Observations include inhibition of growth of freshly derived and continuously passaged breast carcinoma cells in vitro, decreased tumor size and increased survival in spontaneous mouse mammary carcinoma, inhibition of growth of xenogeneic human breast carcinomas grown in nude mice, and reduction of measurable tumors in women. Since clinical doses and schedules have to date been largely empirically derived, additional studies will be required to define optimal clinical use. Furthermore, not all interferon types or subtypes may prove clinically effective. Therefore, use of interferons or interferon inducers in patients should remain restricted to controlled trials with well-defined research objectives.
临床前和临床研究表明，干扰素和干扰素诱导剂对乳腺癌具有抗肿瘤活性。观察结果包括抑制体外新鲜分离和连续传代的乳腺癌细胞生长、减小自发小鼠乳腺癌的肿瘤大小并延长生存期、抑制裸鼠体内异种人乳腺癌的生长，以及减小女性患者可测量肿瘤的大小。由于迄今为止临床剂量和给药方案大多是凭经验确定的，因此需要进一步研究来确定最佳临床应用。此外，并非所有类型或亚型的干扰素在临床上都可能有效。因此，在患者中使用干扰素或干扰素诱导剂应仅限于具有明确研究目标的对照试验。
